RECIST — learning from the past to build the future
- 20 December 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 14 (3), 187-192
- https://doi.org/10.1038/nrclinonc.2016.195
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupEuropean Journal Of Cancer, 2016
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall SurvivalJAMA Internal Medicine, 2015
- Response assessment criteria for brain metastases: proposal from the RANO groupThe Lancet Oncology, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data WarehouseJournal of Clinical Oncology, 2014
- Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid TumorsClinical Cancer Research, 2013
- Review of meta-analyses evaluating surrogate endpoints for overall survival in oncologyOncoTargets and Therapy, 2012
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Issues in Using Progression-Free Survival When Evaluating Oncology ProductsJournal of Clinical Oncology, 2009
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000